Skip to NavigationSkip to content


FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14

The FDA has awarded marketing authorisation to Novartis for the Oral MET inhibitor Tabrecta (capmatinib) for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients whose tumors have a mutation that leads to MET exon 14 skipping (METex14), regardless of whether they have previously received any type of treatment.

The decision, made under accelerated approval, was based on data demonstrating a confirmed overall response rate of 68% with Tabrecta in treatment-naïve METex14 patients and 41% in patients who had previously received treatment.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches